Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. on March 22, 2022. The Company is a Delaware corporation with its principal executive offices in Dallas, Texas, and its common stock trades on The Nasdaq Stock Market under the symbol "LTRN". The filing reports an event occurring on March 22, 2022.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding a corporate action rather than a periodic financial report.
Material Changes
The material event reported is the extension of the Company's existing share repurchase program, as announced in a press release dated March 22, 2022.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors. The press release detailing the share repurchase extension is furnished as Exhibit 99.1 but is explicitly stated not to be deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific terms of the extended share repurchase program, including authorization amounts and duration.
- Verify the Company's current cash position in the most recent 10-Q or 10-K to assess the capacity to fund the repurchase program.
- Check subsequent filings for any updates on the execution of the share repurchase program.